<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03241108</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0101-04</org_study_id>
    <secondary_id>2016-005017-45</secondary_id>
    <nct_id>NCT03241108</nct_id>
  </id_info>
  <brief_title>Study of an Anti-TLR4 mAb in Rheumatoid Arthritis</brief_title>
  <official_title>Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an Anti-Toll Like Receptor 4 Monoclonal Antibody in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovImmune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovImmune SA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international
      multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid
      Arthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study foresees the randomization of at least 81 moderate to severe, ACPA positive, RA
      patients who are inadequate responders to MTX, in two double blind arms (NI-0101:placebo,
      with a ratio of 2:1). Patients will receive NI-0101 or placebo infusions up to a maximum of 6
      administrations (every two weeks for 12 weeks). All patients will continue receiving a stable
      dose of MTX. After 12 weeks, patients will enter the follow up period with monthly visits for
      a minimum of 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">June 20, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, severity, causality and outcomes of Adverse Events (AEs)</measure>
    <time_frame>From screening up to 24 weeks after first treatment administration</time_frame>
    <description>Incidence, severity, causality and outcomes of Adverse Events (AEs) (serious and non-serious), with particular attention being paid to infusion-related reactions and infections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawal for safety reasons</measure>
    <time_frame>From randomization up to 24 weeks after first treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of laboratory parameters</measure>
    <time_frame>From screening up to 24 weeks after first treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of potential circulating antibodies against NI-0101</measure>
    <time_frame>From screening up to 24 weeks after first treatment administration</time_frame>
    <description>Level of potential circulating antibodies against NI-0101 to determine immunogenicity; i.e. the development of anti-drug antibodies (ADA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of CRP</measure>
    <time_frame>From screening up to 24 weeks after first treatment administration</time_frame>
    <description>Levels of C-Reactive protein (CRP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of inflammatory cytokines/chemokines</measure>
    <time_frame>From screening up to 24 weeks after first treatment administration</time_frame>
    <description>IL-6, TNFa, IP-10, MCP-1, sICAM, CXCL13</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DAS28 CRP</measure>
    <time_frame>From screening to 24 weeks after first treatment administration</time_frame>
    <description>Measure of Disease Activity Scores (DAS) for Rheumatism in 28 tender or swollen joints and C-Reactive protein (CRP) - DAS28-CRP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR criteria</measure>
    <time_frame>From randomization to 24 weeks after first treatment administration</time_frame>
    <description>Proportion of patients achieving American College of Rheumatology Criteria (ACR20, ACR50 and ACR70)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patient achieving remission</measure>
    <time_frame>From randomization to 24 weeks after first treatment administration</time_frame>
    <description>Proportion of patient achieving remission (defined as DAS28 &lt; 2.6)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EULAR response</measure>
    <time_frame>From randomization to 24 weeks after first treatment administration</time_frame>
    <description>Proportion of patients achieving European League Against Rheumatism (EULAR) response criteria - good, moderate and no response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Joint Count</measure>
    <time_frame>From screening to 24 weeks after first treatment administration</time_frame>
    <description>Mean number of Tender Joint Count/Swollen Joint Count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SDAI score</measure>
    <time_frame>From randomization to 24 weeks after first treatment administration</time_frame>
    <description>Mean improvement from baseline in Simplified Disease Activity Index (SDAI) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HAQ-DI score</measure>
    <time_frame>From randomization to 24 weeks after first treatment administration</time_frame>
    <description>Mean improvement from baseline in the Health Assessment Questionnaire without Disability Index (HAQ-DI) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36 score</measure>
    <time_frame>from randomization to 24 weeks after first treatment administration</time_frame>
    <description>Mean improvement from baseline in 36-Item Short-Form Health Survey (SF-36) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DAS28-ESR</measure>
    <time_frame>From screening to 24 weeks after first treatment administration</time_frame>
    <description>Measure of Disease Activity Scores (DAS) for Rheumatism in 28 tender or swollen joints and Erythrocyte Sedimentation Rate (ESR) levels - DAS28-ESR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CDAI score</measure>
    <time_frame>From randomization to 24 weeks after first treatment administration</time_frame>
    <description>Mean improvement from baseline in Clinical Disease Activity Index (CDAI) score scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory PK analysis - Cmax</measure>
    <time_frame>From randomization to 24 weeks after first treatment administration</time_frame>
    <description>Peak drug plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory PK analysis - Tmax</measure>
    <time_frame>From screening up to 24 weeks after first treatment administration</time_frame>
    <description>Time when plasma concentration is at peak (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory PK analysis - Ctrough</measure>
    <time_frame>From randomization to 24 weeks after first treatment administration</time_frame>
    <description>Plasma drug concentration immediately prior next dosing (Ctrough)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory PK analysis - AUC</measure>
    <time_frame>From randomization to 24 weeks after first treatment administration</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory PK analysis - CL</measure>
    <time_frame>From randomization to 24 weeks after first treatment administration</time_frame>
    <description>Systemic drug clearance (CL)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>NI-0101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NI-0101</intervention_name>
    <description>Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4</description>
    <arm_group_label>NI-0101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients

          -  Age &gt;= 18 years old

          -  BMI: &lt; 30 and &gt; 18

          -  Diagnosis of RA according to 2010 ACR/EULAR criteria and with a disease duration of at
             least 6 months since diagnosis

          -  Patient must present with active RA, characterized by at least 6 swollen joints out of
             66 assessed and 6 tender joints out of 68 assessed and by the presence of synovitis
             (measured by ultrasound) in at least one of the 6 swollen joints

          -  C-reactive protein (CRP) level &gt; 0.7 mg/dL or if the CRP level is between 0.3 mg/dL
             and 0.7 mg/dL (included) then patient must also present an ESR &gt; 30mm/hr

          -  Patients must have received MTX treatment for at least 3 months and have been on a
             stable dose of MTX for at least 6 weeks prior to start of screening

          -  ACPA-positive RA patients

          -  Women must be postmenopausal (&gt; 12 months without menses) or surgically sterile or
             using two effective contraception methods for at least 4 weeks prior to the
             randomization date and agree to continue contraception for the duration of their
             participation in the study (until the end of follow up period)

          -  Sexually active male patients must use a barrier method of contraception during the
             course of the study (and until the end of the follow up period)

          -  Patients must give written informed consent for study participation

        Exclusion Criteria:

          -  A documented history of an autoimmune disease other than RA by ACR classification, or
             Sjögren syndrome

          -  Administration of cytotoxic drugs and immune suppressants (other than MTX) within 3
             months prior to screening

          -  Previous multiple administrations of any biological DMARD or targeted synthetic DMARD

          -  Known primary immunodeficiency

          -  Pregnant or breastfeeding women

          -  Suspicion of active or latent tuberculosis

          -  HIV, HCV, HBV infection

          -  Infection reported during screening not recovered 72h prior to first dose

          -  History of anaphylactic reactions to any protein therapeutics or excipients

          -  Any history of malignancy, excluding cured basal or squamous cell carcinoma of the
             skin, or cervical in situ carcinoma

          -  Clinically significant cardiac disease requiring medication, such as congestive heart
             failure, unstable angina, myocardial infarction within 6 months prior to randomization

          -  Moderate to severe renal insufficiency, clinically relevant liver function test
             abnormalities or pancytopenia

          -  Major psychiatric or neurological disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest Choy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Infection and Immunity, Cardiff University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic for internal medicine with centre for dialysis</name>
      <address>
        <city>Mostar</city>
        <zip>88000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multi-profile Hospital for Active Treatment &quot;Trimontsium&quot;</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Kaspela&quot;</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Shumen AD</name>
      <address>
        <city>Shumen</city>
        <zip>9705</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active TreatmenT &quot;St. Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARENSIA Phase I Unit at the Research Institute of Clinical Medicine</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Technology Medical Center; University clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Cardiology Center by Acad. G.Chapidze</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insitute of Clinical Cardiology</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi Central Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Clinic Consilium Medulla</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Ltd</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital, ARENSIA Phase I unit</name>
      <address>
        <city>Chisinau</city>
        <zip>MD2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Miriada</name>
      <address>
        <city>Bialystok</city>
        <zip>15-297</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespól Poradni Specjalistycznych REUMED</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Special Hospital for Rheumatic Diseases &quot;Novi Sad&quot;</name>
      <address>
        <city>Novi Sad</city>
        <zip>21112</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Djordje Joanovic&quot;</name>
      <address>
        <city>Zrenjanin</city>
        <zip>23000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>August 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2017</study_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

